UBS lowered the firm’s price target on AMN Healthcare (AMN) to $25.50 from $30 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
- AMN Healthcare Services: Strong Performance and Optimistic Outlook Justify Buy Rating
- AMN Healthcare’s Mixed Earnings Call: Achievements and Challenges
- AMN Healthcare Services: Stabilization Amidst Challenges and Cautious Hold Rating
- AMN Healthcare Reports Q1 2025 Financial Results
- AMN Healthcare sees Q2 revenue $645M-$660M, consensus $648.92M